ReviewCells2021
From NSAIDs to Glucocorticoids and Beyond.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multifunctionality of Calebin A in inflammation, chronic diseases and cancer.Frontiers in oncology · 2022Pooled it
- Discovery and synthesis of phenylthiophene sulfonamide derivatives with promising anti-inflammatory activity.RSC advances · 2026Article
- Gnetum montanum extract attenuates lipopolysaccharide induced acute lung inflammation through Nrf2 and heme oxygenase 1 mediated redox modulation in macrophages.Scientific reports · 2026Article
- Multimodal Topical Formulations Combining Synthetic Anti-Inflammatory Agents, Levofloxacin, and Plant Extracts for Veterinary Wound and Inflammation Care: In Vivo Efficacy.Veterinary sciences · 2026Article
- Reversion of multidrug resistance in clinical isolates of Escherichia coli using non-steroidal anti-inflammatory drugs (NSAIDs).The Journal of antibiotics · 2026Article
- Biomimetic core-shell GelMA microspheres co-delivering ANXA1, NGF, and fibronectin enable phase-matched immunomodulation and neurorepair after spinal cord injury.Theranostics · 2026Article
- Dual-Algorithm Integration Framework Reveals Qing-Wei-Zhi-Tong's Dual Mechanisms in Chronic Gastritis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Immune checkpoint inhibitor-related arthritis and oral disorders: shared pathophysiology and clinical implications for rheumatology and oral health.Cancer cell international · 2025Review
- Exploring herbal synergies in the management of rheumatoid arthritis: a multifaceted approach to inflammation and joint health.Inflammopharmacology · 2025Review
- Polymer-Based Scaffolds Incorporating Selected Essential Oil Components for Wound Healing: A Review.Pharmaceutics · 2025Review
- Associations of genetic proxies for non-steroidal anti-inflammatory drugs with increased kidney stone risk: a Mendelian randomization study.Inflammopharmacology · 2025Article
- Failure to resolve inflammation contributes to juvenile onset cardiac damage in a mouse model of Duchenne muscular dystrophy.Cell death & disease · 2025Article
- Targeting rheumatoid arthritis risk factors with phytochemicals: an anti-inflammatory perspective.Inflammopharmacology · 2025Review
- Ferulic Acid as an Anti-Inflammatory Agent: Insights into Molecular Mechanisms, Pharmacokinetics and Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of Retinal Microvascular Changes in Axial Spondyloarthritis Using Optical Coherence Tomography Angiography: Anti-TNF vs. NSAID Therapy.Diagnostics (Basel, Switzerland) · 2025Article
- The Effect of Dexamethasone Administration on Postoperative Pain Following Laparoscopic Cholecystectomy: A Double-Blind Randomized Clinical Trial.Advanced biomedical research · 2025Article
- Rheumatoid Arthritis: Pathogenesis, Therapeutic Strategies, Advances, and Structural Activity Relationships of Synthesized Agents.Current topics in medicinal chemistry · 2025Review
- A new 3-arylbenzofuran derivative EIE-2 reestablishes Treg-dependent tolerance in rheumatoid arthritis by targeting on Syk induced mTOR and PKCθ imbalance.Frontiers in immunology · 2025Article
- Anti-arthritic studies of ethnomedicine Gaultheria trichophylla Royle extract and salicylate-rich fraction using complete Freud's adjuvant-induced rats: molecular docking and network pharmacology analysis.Inflammopharmacology · 2024Article
- Anti-Inflammatory and Antioxidant Activities of Eugenol: An Update.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our interest in inflammation and its treatment stems from ancient times. Hippocrates used willow bark to treat inflammation, and many centuries later, salicylic acid and its derivative aspirin's ability to inhibit cyclooxygenase enzymes was discovered. Glucocorticoids (GC) ushered in a new era of treatment for both chronic and acute inflammatory disease, but their potentially dangerous side effects led the pharmaceutical industry to seek other, safer, synthetic GC drugs. The discovery of the GC-inducible endogenous anti-inflammatory protein annexin A1 (AnxA1) and other endogenous proresolving mediators has opened a new era of anti-inflammatory therapy. This review aims to recapitulate the last four decades of research on NSAIDs, GCs, and AnxA1 and their anti-inflammatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.